摘要
目的探讨TopoⅡα、GSTπ、Pgp在卵巢癌化疗耐药中的作用。方法采用免疫组化SP法、计算机图像分析技术对80例卵巢癌、20例良性上皮性卵巢肿瘤、20例正常卵巢组织中TopoⅡα、GSTπ、Pgp的表达进行检测。结果卵巢癌中TopoⅡα、GSTπ、Pgp的表达显著高于正常组及良性肿瘤组,P<0.05。TopoⅡα、GSTπ的表达与肿瘤分化程度有关,分化越差表达越高,P<0.05;Pgp的表达与多种病理因素无关,P>0.05。术前化疗组GSTπ、Pgp的阳性表达率显著高于术前未化疗组,P<0.05。结论TopoⅡα、GSTπ、Pgp在卵巢癌耐药中发挥重要作用,这三项指标的联合检测对制定合理的化疗方案具有积极的指导意义。
Objective To investigate the role Topo Ⅱα. GST-π, P-gp played in multidrug resistance of the epithelial ovarian carcinoma. Methods The expression of Topo Ⅱα. GST-π. P-gp in 80 cases of ovarian carcinoma, 20 cases of benign ovarian tumor and 20 cases of normal control were determined by SP immunohistochemical technique. Results The positive expression rate of Topo Ⅱα,GST-π.P-gp in ovarian carcinoma was significantly higher than in benign tumors and normal tissues, P〈0. 05. A significant relationship was shown between Topo Ⅱα.GST-π expression and pathologic grade as well as clinical stage, respectively, P〈0. 05; No significant differences with P-gp expression were found in relation to the histopathology, pathelogic grade and clinical stage, P〈0. 05. The GST-π,P-gp positive expressions in cases received chemotherapy before surgery were significantly higher than in cases who didn＇ t, P〈0. 05. Conclusion These data suggested that Topo Ⅱα. GST-π, P-gp played an important role in the muhidrug resistance of the ovarian carcinoma.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2006年第3期197-199,F0003,共4页
Cancer Research on Prevention and Treatment
